The course of cancer-related insomnia

• Verfasst von: Schieber, Katharina [VerfasserIn]
• Verfasst von: Niecke, Alexander [VerfasserIn]
• Verfasst von: Geiser, Franziska [VerfasserIn]
• Verfasst von: Erim, Yesim [VerfasserIn]
• Verfasst von: Bergelt, Corinna [VerfasserIn]
• Verfasst von: Büttner-Teleaga, Antje [VerfasserIn]
• Verfasst von: Maatouk, Imad [VerfasserIn]
• Verfasst von: Stein, Barbara [VerfasserIn]
• Verfasst von: Teufel, Martin [VerfasserIn]
• Verfasst von: Wickert, Martin [VerfasserIn]
• Verfasst von: Wuensch, Alexander [VerfasserIn]
• Verfasst von: Weis, Joachim [VerfasserIn]
• Titel: The course of cancer-related insomnia
• Titelzusatz: don't expect it to disappear after cancer treatment
• Verf.angabe: Katharina Schieber, Alexander Niecke, Franziska Geiser, Yesim Erim, Corinna Bergelt, Antje Büttner-Teleaga, Imad Maatouk, Barbara Stein, Martin Teufel, Martin Wickert, Alexander Wuensch, Joachim Weis
• E-Jahr: 2019
• Jahr: 11 March 2019
• Umfang: 7 S.
• Fussnoten: Gesehen am 06.02.2020
• Titel Quelle: Enthalten in: Sleep medicine
• Ort Quelle: Amsterdam [u.a.] : Elsevier, 2000
• Jahr Quelle: 2019
• Band/Heft Quelle: 58(2019), Seite 107-113
• ISSN Quelle: 1878-5506
• DOI: doi:10.1016/j.sleep.2019.02.018
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Cancer
• Sach-SW: Gender-specific predictors
• Sach-SW: Insomnia
• Sach-SW: Prevalence
• Sach-SW: Psychological distress
• Sach-SW: Sleep disorder
• K10plus-PPN: 1689519517

Abstract

Objective - The study aimed to examine the 12-month course of cancer-related insomnia (CRI) and to identify possible predictors for the prevalence and persistence of CRI. - Methods - This longitudinal multicenter study included N = 405 patients with cancer (56% females, mean age: 58.6 years). CRI was measured by the Insomnia Severity Index (ISI). Socio-demographic and clinical data, as well as psychological parameters (Distress Thermometer, PHQ-9, GAD-7, and EORTC-Fatigue), were assessed at baseline (T1) and 12 months later (T2). - Results - In our sample, a high prevalence of relevant insomnia symptoms (49.4%, ISI > 7) was found, while a clinical insomnia diagnosis was verified in 12.8% (ISI > 14). When insomnia was present at T1, this problem was persistent after one year in 64%. At T2, however, significantly more women suffered from insomnia symptoms (53.3% women vs. 39.3% men; p = 0.003). Insomnia was associated with many clinical and psychological parameters, especially with fatigue (r = 0.5). Multiple regression analysis revealed that, in women, only insomnia at T1 was a significant predictor for insomnia at T2 (R2 = 0.40; F(5) = 12.5; p < 0.001), whereas in men insomnia, depressive symptoms and the use of psychotropic drugs at T1 predicted the extent of insomnia at T2 (R2 = 0.28; F(7) = 9.5; p < 0.001). In all participants, levels of distress, depression, and anxiety decreased from T1 to T2 (p's < 0.016). - Conclusion - Insomnia is a common disorder in cancer patients. Although medical and psychological parameters improved during the 12-month course of cancer treatment, our results show that insomnia is highly persistent, especially in women. This indicates that adequate support for those affected is needed. Clinical Trial Registration Number: DRKS00004860.